355 related articles for article (PubMed ID: 27274266)
1. The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery - subgroup analyses from 17,701 patients in the XAMOS study.
Haas S; Holberg G; Kreutz R; Lassen MR; Mantovani L; Haupt V; Vogtländer K; Turpie AG
Vasc Health Risk Manag; 2016; 12():209-18. PubMed ID: 27274266
[TBL] [Abstract][Full Text] [Related]
2. Rivaroxaban for Thromboprophylaxis After Fracture-Related Orthopedic Surgery in Routine Clinical Practice.
Lassen MR; Haas S; Kreutz R; Mantovani LG; Holberg G; Turpie AG
Clin Appl Thromb Hemost; 2016 Mar; 22(2):138-46. PubMed ID: 26408640
[TBL] [Abstract][Full Text] [Related]
3. Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital.
Cieri NE; Kusmierski K; Lackie C; Van Opdorp A; Hassan AK
Pharmacotherapy; 2017 Feb; 37(2):170-176. PubMed ID: 28028830
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban: an oral factor Xa inhibitor.
Thomas TF; Ganetsky V; Spinler SA
Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
[TBL] [Abstract][Full Text] [Related]
5. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study.
Cohoon KP; De Sanctis Y; Haskell L; McBane RD; Spiro TE
J Thromb Haemost; 2018 Jul; 16(7):1278-1287. PubMed ID: 29753308
[TBL] [Abstract][Full Text] [Related]
6. A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment.
Turpie AG; Haas S; Kreutz R; Mantovani LG; Pattanayak CW; Holberg G; Jamal W; Schmidt A; van Eickels M; Lassen MR
Thromb Haemost; 2014 Jan; 111(1):94-102. PubMed ID: 24154549
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co-medication interactions.
Kreutz R; Haas S; Holberg G; Lassen MR; Mantovani LG; Schmidt A; Turpie AG
Br J Clin Pharmacol; 2016 Apr; 81(4):724-34. PubMed ID: 26580706
[TBL] [Abstract][Full Text] [Related]
8. Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery.
Turpie AG; Schmidt AC; Kreutz R; Lassen MR; Jamal W; Mantovani L; Haas S
Vasc Health Risk Manag; 2012; 8():363-70. PubMed ID: 22701330
[TBL] [Abstract][Full Text] [Related]
9. Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
Khorana AA; Vadhan-Raj S; Kuderer NM; Wun T; Liebman H; Soff G; Belani C; O'Reilly EM; McBane R; Eikelboom J; Damaraju CV; Beyers K; Dietrich F; Kakkar AK; Riess H; Peixoto RD; Lyman GH
Thromb Haemost; 2017 Nov; 117(11):2135-2145. PubMed ID: 28933799
[TBL] [Abstract][Full Text] [Related]
10. Retrospective Evaluation of Postoperative Bleeding Events in Patients Receiving Rivaroxaban After Undergoing Total Hip and Total Knee Arthroplasty: Comparison with Clinical Trial Data.
Wood RC; Stewart DW; Slusher L; El-Bazouni H; Cluck D; Freshour J; Odle B
Pharmacotherapy; 2015 Jul; 35(7):663-9. PubMed ID: 26095331
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban for Thromboprophylaxis After Nonelective Orthopedic Trauma Surgery in Switzerland.
Hoffmeyer P; Simmen H; Jakob M; Sommer C; Platz A; Ilchmann T; Grossen E; Ryf C; Christofilopoulos P; Schueler M; Lassen MR; Rimle M; Gasser UE
Orthopedics; 2017 Mar; 40(2):109-116. PubMed ID: 27874908
[TBL] [Abstract][Full Text] [Related]
12. [Rivaroxaban versus standard of care in venous thromboembolism prevention following hip or knee arthroplasty in daily clinical practice (Spanish data from the international study XAMOS)].
Granero J; Díaz de Rada P; Lozano LM; Martínez J; Herrera A;
Rev Esp Cir Ortop Traumatol; 2016; 60(1):44-52. PubMed ID: 26194908
[TBL] [Abstract][Full Text] [Related]
13. Budget Impact of Rivaroxaban for the Prevention of Thromboembolic Events after Hip or Knee Replacement in Spain.
Granero Xiberta X; Murcia A; Troncoso Durán JR; Gómez Zubeldia C; Llorac Moix A; Graefenhain De Codes R; Ferrario MG; Lizán L
J Health Econ Outcomes Res; 2016; 4(1):35-46. PubMed ID: 34430666
[No Abstract] [Full Text] [Related]
14. Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial.
Yhim HY; Choi WI; Kim SH; Nam SH; Kim KH; Mun YC; Oh D; Hwang HG; Lee KW; Song EK; Kwon YS; Bang SM
Korean J Intern Med; 2019 Sep; 34(5):1125-1135. PubMed ID: 29788694
[TBL] [Abstract][Full Text] [Related]
15. A RCT study of Rivaroxaban, low-molecular-weight heparin, and sequential medication regimens for the prevention of venous thrombosis after internal fixation of hip fracture.
Tang Y; Wang K; Shi Z; Yang P; Dang X
Biomed Pharmacother; 2017 Aug; 92():982-988. PubMed ID: 28605879
[TBL] [Abstract][Full Text] [Related]
16. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
Raskob GE; Spyropoulos AC; Zrubek J; Ageno W; Albers G; Elliott CG; Halperin J; Haskell L; Hiatt WR; Maynard GA; Peters G; Spiro T; Steg PG; Suh EY; Weitz JI
Thromb Haemost; 2016 Jun; 115(6):1240-8. PubMed ID: 26842902
[TBL] [Abstract][Full Text] [Related]
17. New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban.
Borris LC
Vasc Health Risk Manag; 2008; 4(4):855-62. PubMed ID: 19066002
[TBL] [Abstract][Full Text] [Related]
18. [Rivaroxaban for thrombosis prophylaxis in extensive hip and knee operations. Subanalysis of the German cohort (XAMOS-DE) of non-interventional study XAMOS].
Mouret P; Kreutz R; Deilmann K; Dihlmann A; Holberg G; Haas S
MMW Fortschr Med; 2017 Oct; 159(Suppl 6):26-33. PubMed ID: 29557090
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Novel Oral Anticoagulants vs Low Molecular Weight Heparin for Thromboprophylaxis in Large-Volume Liposuction and Body Contouring Procedures.
Morales R; Ruff E; Patronella C; Mentz H; Newall G; Hustak KL; Fortes P; Bush A
Aesthet Surg J; 2016 Apr; 36(4):440-9. PubMed ID: 26961988
[TBL] [Abstract][Full Text] [Related]
20. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
